LAVANOX® wound irrigation solution and wound spray are used for cleaning wounds and as prophylaxis against infection; they are used for both acute and chronic wounds, especially contaminated and dirty wounds with a high risk of infection. LAVANOX® wound irrigation solution and LAVANOX® wound spray help to remove biofilm and fibrin efficiently and gently, and cause minimal pain when used in the removal of wound inlays and dressings that are encrust- ed and difficult to detach.
Method of use
First of all, clean any dirt, blood and deposits from the wound. Then irrigate the affected area generously with LAVANOX® or spray several times to wet the area completely.
After using LAVANOX®, there is no need to clean the wound with any other solution. There are no restrictions on the frequency or duration of use. LAVANOX® products cause no irritation and minimal pain.
Innovative dosage form
After opening: 12 weeks
Unopened: 2 years from date of manufacture
Water, <0.08% sodium hypochlorite (electronically activated mineral salt solution)
- LAVANOX®Version 03/2017 - Art.Nr. 851196
The electrolytic process reduces the cluster size of the water from 15-20 molecules to about 5-7 molecules, thereby greatly diminishing the surface tension.1,4 This allows effective irrigation of even the most inaccessible areas of the wound. Sodium hypochlorite is both a preservative and an oxidising agent. Thanks to its broad spectrum of activity against bacteria (including Pseudomonas aeruginosa, MRSA/MDRO), viruses and fungi, non-specific decontamination of wounds is possible. 1,4
LAVANOX® is well tolerated by the tissues, as has been confirmed by cytotoxicity studies. In the hen’s egg test on chorioallantoic membrane (HET-CAM), LAVANOX® caused no changes at all or only minimal irritation1. Allergy testing (patch testing) did not reveal any sensitisation and there were likewise no toxic or irritant effects on the tissue.1
Healthy cells have natural protective mechanisms against the redox processes initiated by sodium hypochlorite and are therefore not affected by LAVANOX®.4
After their use, LAVANOX® products regress to their natural state – water and salt.4 There is no environmental impact from their production, use or disposal. LAVANOX® medical devices have purely physical effects, making the products environmentally friendly alternatives for many different uses.
Production and stability
Simplified diagram of a bacterium after the application of LAVANOX®
Sodium hypochlorite (NaOCl) is an oxidising agent that splits off and releases oxygen (O). This free oxygen damages bacterial, viral and fungal cell membranes and increases their permeability. The membrane can no longer withstand the osmotic pressure and the micro-organism is inactivated.1,3,4 After oxygen is split off from the sodium hypochlorite, the substance reverts to its natural state of water and salt.4 Sodium hypochlorite is also produced naturally in the body by lysosomes to defend against micro-organisms and is an important part of phagocytosis in the body’s immune defence mechanisms. But the concentration of "active chlorine" produced is so low that human tissues are not damaged.3
Electrochemical activation (ECA) involves passing an aqueous mineral salt solution through several electrolysis cells. ECA technology represents the further development and optimisation of membrane electrolysis for use in the eld of medicine.
The solutions have particular physicochemical and catalytic properties and are well-established in the decontamination and irrigation of wounds and in keeping wounds moist.
Stable and very well-tolerated solutions are produced from natural starting materials such as water and mineral salts.
1 Brill FHH. Data on file. 2013
2 Kammerlander G, Assadian O, Eberlein T, Zweitmuller P, Luchsinger S, Andriessen A. A clinical evaluation of the efficacy and safety of singlet oxygen in cleansing and disinfecting stagnating wounds. J Wound Care. 2011 Apr;20(4):149-50
3 Kramer A. Wundantiseptik. ARS MEDICI. 2016 (9): 419-426
4 Lorberth J, Massa W. Zu den chemischen Grundlagen der Wirkung von Steralythen. Wund Management 2012 (3): 52-54
5 Möller A, Splieth B, Schmitz M, Eberlein T. Produkte auf Basis elektrochemischer Aktivierung (ECA) im erweiterten medizinischen Einsatz. Medizin & Praxis. 2016 (in Druck)